Table 3.
Comparison of hemoglobin A1c change from baseline in different treatment groups
|
|
Studies
|
Participants
|
WMD
|
95%CI
|
P
value
|
|
| HbA1c change | ||||||
| DPP-4 inhibitors | 6 | 166/166 | -0.42 | -0.58 | -0.25 | < 0.0001 |
| GLP-1 RAs | 7 | 1210/809 | -0.29 | -0.85 | 0.26 | 0.30 |
| SGLT2 inhibitors | 5 | 146/135 | -0.36 | -0.80 | 0.08 | 0.11 |
| HbA1c change (placebo-controlled studies only) | ||||||
| DPP-4 inhibitors | 5 | 102/102 | -0.38 | -0.71 | -0.05 | 0.02 |
| GLP-1 RAs | 3 | 1009/566 | -0.88 | -1.56 | -0.19 | 0.01 |
| SGLT2 inhibitors | 1 | 21/21 | -0.50 | -0.84 | -0.16 | 0.004 |
HbA1c: Hemoglobin A1c; WMD: Weighted mean difference; CI: Confidence interval; DPP-4: Dipeptidyl peptidase-4; GLP-1 RA: Glucagon-like peptide-1 receptor agonists; SGLT2: Sodium-glucose cotransporter 2.